In a recent collaborative effort, Takeda Pharmaceuticals International, Inc., Harvard Medical School and CHDR have assessed Transcranial Magnetic Stimulation (TMS) as a translational biomarker for modulation of AMPA receptor function. Therefore, the effect of administering AMPAkine TAK-653 on TMS-induced MMG amplitudes was tested in rats, and TMS-elicited MEP responses were assessed as a translational biomarker for neural circuit modulation by TAK-653 in humans.
Both studies and results are summarized in this poster.
